合計 50 件の最近のインサイダー取引記録が記録されています Ocular Therapeutix, Inc. (OCUL), 内訳は 19 件の買い および 24 件の売り. インサイダー買い総額は $44.07M インサイダー売り総額は $3.1M.
最近活動のある主要インサイダーには Heier Jeffrey S., Dugel Pravin, Kaiser Peter. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — OCUL
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-02-23 |
Heier Jeffrey S. |
Chief Scientific Officer |
情報に基づく売り |
3,057 |
$8.28 |
$25.31K |
323,368 |
| 2026-02-23 |
Dugel Pravin |
See Remarks |
情報に基づく売り |
20,056 |
$8.28 |
$166.06K |
3,013,022 |
| 2026-02-23 |
Kaiser Peter |
Chief Development Officer |
情報に基づく売り |
2,810 |
$8.28 |
$23.27K |
269,108 |
| 2026-02-23 |
Nayak Sanjay |
Chief Strategy Officer |
情報に基づく売り |
1,759 |
$8.28 |
$14.56K |
330,653 |
| 2026-02-20 |
Lindstrom Richard L Md |
Director |
情報に基づく買い |
60,229 |
$7.66 |
$461.35K |
246,933 |
| 2026-02-20 |
Waheed Nadia |
Chief Medical Officer |
情報に基づく売り |
3,510 |
$7.74 |
$27.17K |
314,907 |
| 2026-02-12 |
Dugel Pravin |
See Remarks |
情報に基づく売り |
124,882 |
$9.04 |
$1.13M |
3,033,078 |
| 2026-02-12 |
Notman Donald |
Chief Operating Officer |
情報に基づく売り |
11,446 |
$9.04 |
$103.47K |
366,356 |
| 2026-02-12 |
Nayak Sanjay |
Chief Strategy Officer |
情報に基づく売り |
10,348 |
$9.04 |
$93.55K |
332,412 |
| 2026-02-12 |
Waheed Nadia |
Chief Medical Officer |
情報に基づく売り |
7,863 |
$9.04 |
$71.08K |
318,417 |
| 2026-02-04 |
Notman Donald |
Chief Operating Officer |
情報に基づく売り |
6,035 |
$8.54 |
$51.54K |
377,802 |
| 2026-02-02 |
Notman Donald |
Chief Operating Officer |
情報に基づく売り |
5,455 |
$9.14 |
$49.86K |
383,837 |
| 2026-01-21 |
Robinson David Wayne |
Officer |
不明 |
- |
- |
- |
- |
| 2026-01-21 |
Robinson David Wayne |
Global Cco |
RSU 付与（制限付株式） |
136,000 |
- |
- |
136,000 |
| 2026-01-20 |
Robins Jason Shand |
Interim CFO |
不明 |
110,600 |
$8.12 |
$898.07K |
- |
| 2026-01-20 |
Robins Jason Shand |
Interim CFO |
RSU 付与（制限付株式） |
33,000 |
$11.45 |
$377.85K |
33,000 |
| 2026-01-02 |
Heier Jeffrey S. |
Chief Scientific Officer |
RSU 付与（制限付株式） |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Notman Donald |
See Remarks |
RSU 付与（制限付株式） |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Kaiser Peter |
Chief Development Officer |
RSU 付与（制限付株式） |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Nayak Sanjay |
Chief Strategy Officer |
RSU 付与（制限付株式） |
197,650 |
$11.82 |
$2.34M |
197,650 |
| 2026-01-02 |
Waheed Nadia |
Chief Medical Officer |
RSU 付与（制限付株式） |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Anderman Todd |
Chief Legal Officer |
RSU 付与（制限付株式） |
64,900 |
- |
- |
152,468 |
| 2026-01-02 |
Saroj Namrata |
Chief Business Officer |
RSU 付与（制限付株式） |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Meyers Steve Lawrence |
Chief Commercial Officer |
RSU 付与（制限付株式） |
197,650 |
$11.82 |
$2.34M |
197,650 |
| 2025-11-26 |
Dugel Pravin |
See Remarks |
贈与（送付） |
49,754 |
- |
- |
- |
| 2025-11-24 |
Heier Jeffrey S. |
Chief Scientific Officer |
情報に基づく売り |
3,469 |
$12.04 |
$41.77K |
245,940 |
| 2025-11-24 |
Dugel Pravin |
See Remarks |
情報に基づく売り |
19,530 |
$12.04 |
$235.14K |
3,157,960 |
| 2025-11-24 |
Kaiser Peter |
Chief Development Officer |
情報に基づく売り |
3,007 |
$12.02 |
$36.14K |
191,433 |
| 2025-11-24 |
Nayak Sanjay |
Chief Strategy Officer |
情報に基づく売り |
1,878 |
$12.04 |
$22.61K |
277,860 |
| 2025-11-05 |
Saroj Namrata |
Chief Business Officer |
情報に基づく売り |
25,865 |
$10.74 |
$277.79K |
174,135 |
| 2025-10-08 |
Anderman Todd |
Chief Legal Officer |
情報に基づく売り |
11,132 |
$12.34 |
$137.37K |
87,568 |
| 2025-10-02 |
Heier Jeffrey S. |
Chief Scientific Officer |
情報に基づく売り |
10,502 |
$11.04 |
$115.94K |
249,409 |
| 2025-10-02 |
Kaiser Peter |
Chief Development Officer |
情報に基づく売り |
9,653 |
$11.03 |
$106.47K |
194,440 |
| 2025-09-09 |
Dugel Pravin |
See Remarks |
贈与（受領） |
49,754 |
- |
- |
49,754 |
| 2025-09-02 |
Notman Donald |
See Remarks |
情報に基づく売り |
1,066 |
$12.43 |
$13.25K |
308,807 |
| 2025-08-25 |
Heier Jeffrey S. |
Chief Scientific Officer |
情報に基づく売り |
3,063 |
$12.04 |
$36.88K |
259,911 |
| 2025-08-25 |
Dugel Pravin |
See Remarks |
情報に基づく売り |
21,494 |
$12.04 |
$258.79K |
3,227,244 |
| 2025-08-25 |
Kaiser Peter |
Chief Development Officer |
情報に基づく売り |
3,011 |
$12.04 |
$36.25K |
204,093 |
| 2025-08-25 |
Nayak Sanjay |
Chief Strategy Officer |
情報に基づく売り |
1,885 |
$12.04 |
$22.7K |
279,738 |
| 2025-08-12 |
Waheed Nadia |
Chief Medical Officer |
RSU 付与（制限付株式） |
122,923 |
$12.48 |
$1.53M |
122,923 |
| 2025-08-11 |
Dugel Pravin |
See Remarks |
贈与（受領） |
250,361 |
- |
- |
250,361 |
| 2025-06-12 |
Dugel Pravin |
See Remarks |
贈与（送付） |
50,029 |
- |
- |
3,248,738 |
| 2025-06-11 |
Raines Merilee |
Director |
RSU 付与（制限付株式） |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Lindstrom Richard L Md |
Director |
RSU 付与（制限付株式） |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Graves Adrienne L |
Director |
RSU 付与（制限付株式） |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Warden Charles M |
Director |
RSU 付与（制限付株式） |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Dugel Pravin |
See Remarks |
RSU 付与（制限付株式） |
2,750,000 |
$7.44 |
$20.46M |
2,750,000 |
| 2025-06-11 |
Williams Leslie J. |
Director |
RSU 付与（制限付株式） |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Hong Seung Suh |
Director |
RSU 付与（制限付株式） |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Saroj Namrata |
Chief Business Officer |
不明 |
316,000 |
$10.27 |
$3.25M |
- |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
